ArticleInternational journal of colorectal disease2008
Cholestyramine--a useful adjunct for the treatment of patients with fecal incontinence.
Article in International journal of colorectal disease, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.
- Biofeedback for the treatment of female pelvic floor muscle dysfunction: a systematic review and meta-analysis.International urogynecology journal · 2012Pooled it
- A randomized double-blind trial of clonidine and colesevelam for women with fecal incontinence.Neurogastroenterology and motility · 2024Trial
- Development of a new version of the Bristol Stool Form Scale: translation, content validity, face validity, and reliability of the Persian version.BMJ open gastroenterology · 2022Article
- Faecal incontinence in adults.Nature reviews. Disease primers · 2022Review
- Constipation and Fecal Incontinence in the Elderly.Current gastroenterology reports · 2020Review
- Rationale for Investigating Stool Metabolites and Microbiota in Women With Fecal Incontinence.Diseases of the colon and rectum · 2017Article
- Evidence-Based Update on Treatments of Fecal Incontinence in Women.Obstetrics and gynecology clinics of North America · 2016Review
- Faecal incontinence: Current knowledges and perspectives.World journal of gastrointestinal pathophysiology · 2016Review
- Food, fibre, bile acids and the pelvic floor: An integrated low risk low cost approach to managing irritable bowel syndrome.World journal of gastroenterology · 2015Review
- Clinical Challenges of Fecal Incontinence in the Elderly.Current treatment options in gastroenterology · 2015Article
- Treatment of fecal incontinence: state of the science summary for the National Institute of Diabetes and Digestive and Kidney Diseases workshop.The American journal of gastroenterology · 2015Article
- Management of pelvic floor disorders: biofeedback and more.Current treatment options in gastroenterology · 2014Article
- Medical management of fecal incontinence in challenging populations: a review.Clinics in colon and rectal surgery · 2014Review
- Bowel disturbances are the most important risk factors for late onset fecal incontinence: a population-based case-control study in women.Gastroenterology · 2010Article
- Survey of geriatricians on the effect of fecal incontinence on nursing home referral.Journal of the American Geriatrics Society · 2010Article
- Bowel management for the treatment of pediatric fecal incontinence.Pediatric surgery international · 2009Review
- Outcomes of combination treatment of fecal incontinence in women.American journal of obstetrics and gynecology · 2008Article
- Urinary and fecal incontinence in nursing home residents.Gastroenterology clinics of North America · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
AIM/
backgroundCholestyramine may improve fecal incontinence, but its use has not been assessed. We report our experience with the use of cholestyramine in the treatment of fecal incontinence. MATERIALS AND
methodsTwenty-one patients (19 female, mean age 65 years) with fecal incontinence (>/=1 episode/week) received cholestyramine along with biofeedback therapy (group A). Stool frequency, stool consistency (Bristol scale), number of incontinent episodes, satisfaction with bowel function (VAS), and anorectal physiology were assessed at 3 months and at 1 year after treatment. Data were compared with a matched group of 21 incontinent subjects (19 female, mean age 64 years) who received biofeedback alone (group B).
resultsAt 3 months and at 1 year, group A patients showed decreased stool frequency (p < 0.01), stool consistency (p = 0.001), and number of incontinent episodes (p < 0.04). In contrast, stool frequency (p = 0.8) and stool consistency (0.23) were not different from baseline in group B subjects. In both groups, there was improvement in the satisfaction with bowel function (p < 0.05), anal sphincter pressures (p < 0.05) and ability to retain saline infusion (p < 0.05). Mean dose of cholestyramine used was 3.6 g; 13 subjects (62%) required dose titration, and 7 (33%) subjects reported minor side effects.
conclusionCholestyramine is safe and useful adjunct for the treatment of diarrhea and fecal incontinence. Most patients require small doses, and dose titration is important. The improvement in stool characteristics favors a drug effect, over and above the benefits of biofeedback therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.